Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amarin Corporation plc AMRN

Healthcare Biotechnology
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult... see more

Recent & Breaking News (NDAQ:AMRN)

Amarin Partner HLS Therapeutics Completes Reimbursement Negotiations with Pan-Canadian Pharmaceutical Alliance (pCPA) for VASCEPA® (icosapent ethyl)

GlobeNewswire April 26, 2022

Amarin to Report First Quarter 2022 Financial Results and Host Conference Call On May 4, 2022

GlobeNewswire April 19, 2022

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

GlobeNewswire April 1, 2022

Amarin Receives Reimbursement for VAZKEPA® in Sweden

GlobeNewswire March 28, 2022

Latest Research Evaluating VASCEPA® (Icosapent Ethyl) to be Presented at the American College of Cardiology's 71st Annual Scientific Session

GlobeNewswire March 21, 2022

Latest analysis shows VASCEPA® (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events in patients with prior percutaneous coronary intervention

GlobeNewswire March 10, 2022

Amarin Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 1, 2022

Amarin to Participate in Cowen 42nd Annual Health Care Conference

GlobeNewswire February 25, 2022

JAMA Publication Highlights VASCEPA® (Icosapent Ethyl) Cardiovascular Risk Reduction Extends to Cost Effectiveness at Patient Level

GlobeNewswire February 24, 2022

Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

GlobeNewswire February 15, 2022

Amarin Provides Preliminary 2021 Revenue and Outlook for 2022

GlobeNewswire January 10, 2022

Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

AMRN Final Deadline Tomorrow: Rosen, a Global and Leading Law Firm, Encourages Amarin Corporation plc Investors with Losses to Secure Counsel Before Important December 23 Deadline in Securities Class Action - AMRN

Newsfile December 22, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation PLC, of Class Action Lawsuit and Upcoming Deadline - AMRN

PR Newswire December 21, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Amarin Corporation Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2021 - AMRN

PR Newswire December 21, 2021

AMRN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amarin Corporation plc Investors to Secure Counsel Before Important Thursday Deadline in Securities Class Action - AMRN

Newsfile December 20, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation PLC, of Class Action Lawsuit and Upcoming Deadline - AMRN

Newsfile December 16, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Amarin Corporation Plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2021 - AMRN

PR Newswire December 15, 2021

ROSEN, A LEADING LAW FIRM, Encourages Amarin Corporation plc Investors with Losses in Excess of $100K to Secure Counsel Before Important December 23 Deadline in Securities Class Action - AMRN

PR Newswire December 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amarin Corporation PLC, of Class Action Lawsuit and Upcoming Deadline - AMRN

PR Newswire December 13, 2021